From May 5th to 7th, the 7th Future Medical Top 100 Conference sponsored by VB100, VBdate, and VCBeat Research was grandly held at the Zhangjiang Science Hall in Shanghai. The conference received strong support from the Shanghai Pudong District Government and Zhangjiang Group, and brought together many Chinese and foreign academicians and experts in various fields, including the internationally renowned scientist Professor Robert Langer . Professor Robert Langer’s speech As an expert with many years of experience in pharmaceutical technology transfer, Dr. Tom Du, chairman of Evergreen, hosted a roundtable forum with listed pharmaceutical company in the United States, innovative pharmaceutical companies in China, well-known investment institutions, and pharmaceutical experts from

On June 15, the 6th Future Healthcare Top 100 Conference released a series of lists for 2022. This time, Evergreen Therapeutics was successfully awarded the "Top 100 Biomedicine Companies".Evergreen Awarded as "Top 100 Biomedicine Companies" The Future Healthcare Top 100 List was established in 2015. It is the first domestic innovative medical field list for non-listed companies launched by VB100, VBDATA, and Eggshell Research Institute. It aims to select Chinese innovative medical practitioners who truly represent future medical care, discover the core strength of our country's future medical industry, and promote the innovation and transformation process of the healthcare industry. As an international innovative pharmaceutical company founded just over two years ago, E

On February 4, 2022, Evergreen Therapeutics Co., Ltd. (hereinafter referred to as "Evergreen Therapeutics" or "Evergreen") announced that an oral drug for the treatment of dry macular degeneration with independent intellectual property rights, EG-301, it’s IND was approved by the US FDA and officially entered the phase II clinical trial. EG-301, part of Evergreen Therapeutic’s ophthalmic pipeline, is an oral medication for the treatment of dry maculopathy in patients over 50 years of age. EG-301 has complete safety data in humans and demonstrated efficacy in animal studies. According to statistics, there were about 100 million people with maculopathy in the world in 2020, of which Dry macular disease (AMD) accounted for about 90% of the total number of patients with maculopathy. There

On December 21, 2021 China Pharmaceutical Entrepreneurs, Scientists and Investors Conference  was jointly sponsored by the China Pharmaceutical Enterprise Management Association, China Pharmaceutical Biotechnology Association, and Hangzhou Investment Promotion Bureau, officially held online. The list of "2021 Top 100 Chinese Pharmaceutical Innovative Seed Enterprises" (CPISE 100) was released for the first time at this conference. The top 100 list is a continuation of the basic research framework of "Innovation 100", focusing on innovative foundation, innovative process, and innovative results. The evaluation system, based on Clarivate Analytics' Derwent patent data and Cortellis competitive intelligence and clinical trial data, selects more than 5,000 domestic

On October 18-19, 2021, Evergreen Therapeutics Co., Ltd. held its first offline meeting at the US headquarters since the outbreak in Bethesda, Maryland. Dr. Du Tao, Chairman of the Board, Dr. Du Xin, Chief Executive Officer, Dr. Li Changqing, Chief Medical Officer, COO Kevin Wang, CFO Julia Lu, Clinical and preclinical Division Director, senior consultant of the company and former senior FDA officer Dr. Florence Houn and other members of Evergreen's consulting team attended the meeting. Figure 1: The first meeting of Evergreen's team, department directors and consultantsUnder the chairmanship of Dr. Du Xin, the meeting reviewed the excellent achievements of Evergreen pharmaceutical in the past two years; Dr. Li Changqing, chief Medical Officer, made a systematic

In celebration of “Golden Autumn”, on October 16, 2021, the FDA Experts Association held the North America Golden Autumn Party at Han Palace in North Bethesda, Maryland. Since its establishment in 2019 on the bank of West Lake in Hangzhou, China, the association has grown stronger under the leadership of its presidents (first President, He Ruyi; current President, Du Tao; President-elect, Li Ning) to become a group of nearly 100 people. Members reside throughout China and the United States, with new members continuously joining, including Liu Ke (Senior VP and Director of Regulatory Affairs & Strategy at Sana Biotechnology) and Wang Yaning (CEO of Createrna Science & Technology). New members have brought fresh

During China’s October National Day, news of Merck’s investigational oral pill (Molnupiravir) for treating Covid-19 was received with great excitement and many questions: is a special drug finally born? Will the treatment of Covid-19 be similar to that for the common cold? Will the new drug become the panacea in ending the Covid-19 pandemic? However, shortly thereafter, reports from India indicated that the drug has “no significant efficacy” for patients with moderate Covid-19 symptoms, making it difficult at this time to determine the efficacy of Molnupiravir for treating Covid-19. We at Evergreen are not surprised; as we understand it, according to the 10 technical pathways of vaccine development and 10 EUA products approved by the FDA, every aspect of the fight against SARS-CoV-2 h

Bethesda, Maryland – October 4, 2021 – Evergreen Therapeutics announces that the CMC team, led by Evergreen CEO, Dr. Xin Du, visited its US partner, Pharmaceutics International, Inc. (Pii), and met with the project team to discuss the production of the new anti-coronavirus drug.  Dr. Du and his team visits Pii facility During the meeting, Pii’s project leader introduced and explained the company's production site via video, during which Evergreen’s CMC team discussed possible issues and solutions regarding drug production with each of Pii’s production-line teams. Thereafter, the Evergreen CMC team, guided by Pii team members, also visited several facilities, including the cGMP manufacturing area, the formulation R&D lab, and the cGMP warehouse. Evergr

Dr.Charles Lee, CMO of EvergreenDr. Li Changqing, CMO of Evergreen Therapeutics (“Evergreen” or the “Company”) shared his excitement on the very intuitive demonstration of the efficacy of the EG-007 combination: “Simply comparing the size of tumor residual in the same animal trial, the average tumor weight after dual-drug treatment was approximately 730 mg, while after our three-drug regimen it was just over 300 mg.”EG-007 was the first drug candidate Dr. Li led after joining Evergreen. In mid-July this year, Dr. Li assumed position of Evergreen CMO. Subsequently in August, after two pre-IND meetings, the FDA approved the Phase III pivotal clinical trial protocol of EG-007 in combination with targeted drugs and anti-PD-1 antibody analogs for the treatment of advanced endometrial cancer. No

Evergreen Therapeutics Inc. (hereinafter referred to as "Evergreen Therapeutics" or "Evergreen") announced on September 14, 2021 that DCGI, the Indian regulatory authority, has officially approved the phase II clinical trial of EG-009A for COVID-19 in India.EG-009A is one of Evergreen's 13 R&D pipelines and will be used to treat Cytokine Release Syndrome (CRS) caused by COVID-19 infections. India is one of the major regions where the Delta variant of COVID-19 is prevalent, and the phase II clinical trial was approved to understand the efficacy of EG-009A in patients with moderate to severe COVID-19 caused by the Delta variant. It is understood that this is the world's first clinical trial with COVID-19 Delta variant as the main research target, so it has a great clinical significan